HOMEwww.epgonline.orgDRUGSwww.epgonline.orgDISEASE KNOWLEDGEwww.epgonline.orgGUIDELINESwww.epgonline.orgCLINICAL TRIALSwww.epgonline.orgREGISTERwww.epgonline.orgSEARCH
Members
Why a doctor should
Username/Email

Password ()




EPG on Twitter EPG Online Twitter
EPG Online Blog EPG Online Blog
EPG Online Disease Knowledge Centres Feed Disease Knowledge
Recent UK Drug Updates Drug Updates
EPG Search
Search
Languages

RENAPRO overview
For dialysis patients, for the prevention and treatment of catabolism and cachexia, and hyperphosphatemia. Generally used where there is an increase in protein requirement, particularly when a reduction in phosphate and potassium is indicated. Suitable for use in gluten and fibre-free diets with defined protein and electrolyte content
banner_pass = 1

Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.

Change language Current language database: English
 
 
Related DrugsDrug Details
RENAPRO
Drug Class Description :

Foods (ACBS approved).

Generic Name :

Protein, fat, carbohydrate

Drug description :

Powder. 367kcal/100 g.

Presentation :

Renapro is a powdered protein concentrate that has a low phosphate and low potassium. Box content: 600g (30 x 20g sachets)

Indications :

For dialysis patients, for the prevention and treatment of catabolism and cachexia, and hyperphosphatemia. Generally used where there is an increase in protein requirement, particularly when a reduction in phosphate and potassium is indicated. Suitable for use in gluten and fibre-free diets with defined protein and electrolyte content

Adult Dosage :

According to the physician’s instructions, taking into account the nutritional condition and energy requirements of the patient. Renapro is used to supplement the diet as a drink or food, to prevent and treat conditions of protein deficiency: Haemodialysis therapy: 20 g (1 sachet) Peritoneal dialysis therapy: 20 – 40 g (1 – 2 sachets) Renapro dissolves easily in either cold or warm liquid. It can be cooked or baked and is thus suitable for use in many dishes and drinks.

Renapro is suitable for enriching the protein content of liquid diet and tube fed products, such as Renamil. Open sachets should be used immediately Food: With most foods, Renapro can simply be thinly sprinkled over the surface and slowly stirred in fruit juices, soups, sauces, soft cheese dishes, yoghurt and mashed potatoes. Renapro can be mixed with minced meat and other ingredients in readiness for baking/cooking. Like cheese, Renapro can be used sprinkled on paste and placed under the grill.

Drinks: When added to liquids such as liquid diet preparations, soups and sauces, Renapro must be fully dissolved, it is advisable to use a food processor or mixer and add the mix to the remaining liquid. Premixed solutions should be stored in a refrigerator and used within 24 hours. High-Energy, High-Protein Liquid Diets: When treating a nutritional disorder such as cachexia or Catabolism in dialysis patients, adequate energy intake must also be considered. Where necessary Renapro can be combined with the energy concentrate Renamil in the following proportions: Mix 1 sachet (20g) of Renapro with 1 sachet 9(100g) of Renamil and dissolve in 100 – 500 ml water

Adverse Reactions :

Renapro must be used under medical supervision Renapro is not a complete food and is not suitable for use as a sole source of nutrition.

Renapro should not be used with children under 1 year of age Persons who are allergic to cows milk or who have absorption and digestive problems should not consume Renapro Renapro is not for parenteral use.

Manufacturer :

KoRa Healthcare Ltd

Drug Updated :

21 May 2009

Related Drugs - Modular supplements
Soft Tissue Sarcoma Alzheimer's disease (AD) is a progressive, neurodegenerative disease which will affect most of us at one point in time, and it’s prevalence increases with age. www.hae-awareness.net is a CPD-accredited interactive training programme for physicians involved in the care and treatment of patients with hereditary angioedema Lysosomal storage disorders (LSDs) are a group of progressive and often fatal genetic diseases that are caused by an inborn error of metabolism
New and updated Drugs
UK Drugs EPG Medical News Feed
Spanish Drugs EPG Medical News Feed
German Drugs EPG Medical News Feed
Norweigan Drugs EPG Medical News Feed
Netherlands Drugs EPG Medical News Feed
Swedish Drugs EPG Medical News Feed
French Drugs EPG French Drugs Feed
Portuguese Drugs EPG Portuguese Drugs Feed
Italian Drugs EPG Italian Drugs Feed

Atopic Dermatitis

Atopic Dermatitis

CONNECT

DISEASE CENTRES Disease Centres feed

AFFILIATE PARTNERS

QUICK SEARCH

GUIDELINES UK Drug Data Feed

DRUG DATA UK Drug Data Feed

REFERENCES